ERAS-601 + sotorasib

ERAS-601 + sotorasib is an investigational **oral combination therapy** for cancer. ERAS-601 is a potent, selective, and orally bioavailable allosteric inhibitor of SHP2, a phosphatase that transduces receptor tyrosine kinase signaling to the RAS/MAPK pathway, inhibiting RAS signaling[3]. Sotorasib is an approved, selective, oral small molecule inhibitor targeting the KRAS G12C mutation, a common oncogenic driver in several cancers, notably non-small cell lung cancer (NSCLC)[2][6]. The rationale for combining these agents is to target multiple nodes of the RAS/MAPK pathway for enhanced antitumor activity, particularly in cancers harboring KRAS G12C mutations. Preclinical and early-phase clinical data support this combination in patients with advanced cancers such as NSCLC[3][5][7].

Other names

ERAS-601 + sotorasib